Stay updated on Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial
Sign up to get notified when there's something new on the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page.

Latest updates to the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe web page has been updated to reflect new study objectives and details regarding the incidence of breast and bladder cancer among patients using dapagliflozin. Additionally, the study's recruitment status has changed, and the number of study locations has been adjusted.SummaryDifference14%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check38 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check53 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check60 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.SummaryDifference0.3%
- Check89 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
Stay in the know with updates to Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page.